Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Triple Immunotherapy Overcomes Immune Evasion by Tumor in a Melanoma Mouse Model.

Frontiers in oncology·2020
Same author

Atorvastatin increases the production of proinflammatory cytokines and decreases the survival of Escherichia coli-infected mice.

Scientific reports·2019
Same author

Epstein-Barr virus DNA modulates regulatory T-cell programming in addition to enhancing interleukin-17A production via Toll-like receptor 9.

PloS one·2018
Same author

The Effect of Denatured Flagellin on Toll-Like Receptor-5 (TLR-5) in Mice.

Endocrine, metabolic & immune disorders drug targets·2018
Same author

Atorvastatin Reduces the Survival of Candida albicans-Infected BALB/c Mice.

Frontiers in microbiology·2016
Same author

Laparoscopic donor nephrectomy: The Middle East experience.

Arab journal of urology·2015

Related Experiment Video

Updated: Jun 22, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Patented small molecules against psoriasis.

Alexander M Abdelnoor1

  • 1American University of Beirut, Department of Microbiology & Immunology, Riad el-Solh, Beirut 1107 2020, Lebanon. aanoor@aub.edu.lb

Expert Opinion on Therapeutic Patents
|July 2, 2009
PubMed
Summary

New small molecules targeting intracellular pathways show promise for treating psoriasis. These orally administered drugs offer a novel therapeutic approach by inhibiting key inflammatory processes and promoting cell death.

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Psoriasis is hypothesized to be an autoimmune disease.
  • Current treatments include monoclonal antibodies (mAb)/fusion proteins, with a focus on developing orally administered small molecules.
  • Research is exploring small molecules that target intracellular pathways for antipsoriatic effects.

Purpose of the Study:

  • To review preclinical patented small molecules for psoriasis treatment.
  • To emphasize the mechanisms of action for these small molecules.

Main Methods:

  • Searched Espacenet, Pubmed, Scopus, and Google for patented small molecules.
  • Acknowledged difficulties with poorly described patents and patents indicated for multiple autoimmune diseases.
  • Focused on patents relevant to psoriasis treatment.

Related Experiment Videos

Last Updated: Jun 22, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Main Results:

  • Patented small molecules inhibit T lymphocyte activation, leukocyte trafficking, leukotriene activity/production, and angiogenesis.
  • Promoted apoptosis is also a mechanism targeted by patented small molecules.
  • Several patented small molecules for other autoimmune diseases show potential for psoriasis treatment.

Conclusions:

  • Small molecules offer diverse mechanisms for psoriasis treatment, including immune modulation and apoptosis induction.
  • Repurposing small molecules from other autoimmune disease treatments is a viable strategy.
  • Further investigation into small molecule mechanisms could lead to novel psoriasis therapies.